Pulmonary drug delivery: a role for polymeric nanoparticles?

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Pharmaceutics

Background:

• Pulmonary drug delivery targets lung diseases directly, minimizing systemic side effects.
• The lungs serve as a pathway for systemic drug delivery into the bloodstream via airway surfaces.
• Inhalable carriers, particularly polymeric nanoparticles (NPs), enhance therapeutic outcomes by protecting drugs and aiding transport across lung barriers.

Purpose of the Study:

• To review recent advancements in polymeric nanoparticles (NPs) for pulmonary drug delivery.
• To outline challenges and design principles for engineering inhalable NPs.
• To present the current state of biocompatible polymeric NPs for inhalation, focusing on dry powder formulations.

Main Methods:

• Review of recent literature on polymeric nanoparticles for pulmonary drug delivery.
• Analysis of design rules for engineering inhalable NPs to overcome physiological barriers.
• Presentation of state-of-the-art NP formulations using natural and synthetic biodegradable polymers.
• Discussion of in vitro and in vivo models for evaluating NP safety and efficacy.

Main Results:

• Polymeric NPs are engineered to protect drugs from lung defenses and facilitate transport across biological barriers.
• Inhalable NPs, especially dry powders, show promise for optimized pulmonary and systemic drug delivery.
• Biocompatible NPs derived from natural and biodegradable synthetic polymers are key components.

Conclusions:

• Engineered polymeric nanoparticles represent a significant advancement in pulmonary drug delivery systems.
• Overcoming lung-specific anatomical and physiological challenges is crucial for effective NP-based inhalation therapies.
• Further research using in vitro/in vivo models is necessary to address toxicological concerns and optimize NP formulations for clinical use.